{"url_path":"/sec/pasg/8-k/2026-06-24/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1787297/0001104659-26-077306-index.html","accession_number":"0001104659-26-077306","cik":"0001787297","ticker":"PASG","issuer_name":"Passage BIO, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787297/0001104659-26-077306-index.html","primary_entity_key":"0001787297","primary_entity_name":"Passage BIO, Inc."},"word_count":223,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNumber**\n \n**Exhibit Description**\n\n \n \n\n[2.1^](tm2618476d1_ex2-1.htm)\n \n[Agreement\nand Plan of Merger, dated June 24, 2026, by and among Passage Bio, Inc., Peregrine Merger Sub, Inc., and Remix Therapeutics, Inc.](tm2618476d1_ex2-1.htm)\n\n \n \n\n[10.1](tm2618476d1_ex10-1.htm)\n \n[Form of\nSupport Agreement by and between Passage Bio, Inc. and certain stockholders of Remix Therapeutics, Inc.](tm2618476d1_ex10-1.htm)\n\n \n \n\n[10.2](tm2618476d1_ex10-2.htm)\n \n[Form of\nSupport Agreement by and between Remix Therapeutics, Inc. and certain stockholders of Passage Bio, Inc.](tm2618476d1_ex10-2.htm)\n\n \n \n\n[10.3](tm2618476d1_ex10-3.htm)\n \n[Form of Lock-Up Agreement.](tm2618476d1_ex10-3.htm)\n\n \n \n \n\n[10.4](tm2618476d1_ex10-4.htm)\n \n[Form of Subscription Agreement among Remix Therapeutics, Inc. and the purchasers signatory\nthereto.](tm2618476d1_ex10-4.htm)\n\n \n \n \n\n[10.5](tm2618476d1_ex10-5.htm)\n \n[Form of\nRegistration Rights Agreement among Remix Therapeutics, Inc., Passage Bio, Inc., and the purchasers signatory thereto.](tm2618476d1_ex10-5.htm)\n\n \n \n\n[10.6](tm2618476d1_ex10-6.htm)\n \n[Form of\nCVR Agreement.](tm2618476d1_ex10-6.htm)\n\n \n \n\n[99.1](tm2618476d1_ex99-1.htm)\n \n[Joint Press Release, dated June 24, 2026.](tm2618476d1_ex99-1.htm)\n\n \n \n \n\n[99.2](tm2618476d1_ex99-2.htm)\n \n[Investor Presentation, dated June 24, 2026.](tm2618476d1_ex99-2.htm)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n^            Registrant\nhas omitted schedules and exhibits pursuant to Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish supplementally\na copy of the omitted schedules and exhibits to the SEC upon request.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**PASSAGE BIO, INC.**\n\n \n \n \n\nDate: June 24, 2026\nBy:\n\n/s/ Kathleen Borthwick\n\n \nName:\nKathleen Borthwick\n\n \nTitle:\nChief Financial Officer"}